As Big Pharma braces for a massive revenue crash when patents on blockbuster drugs expire, an unexpected player is stepping into the gap. China’s biotech sector is central could ally with Western drugmakers—unless geopolitics gets in the way.
As Big Pharma faces a 'patent cliff', China’s biotech boom is emerging as the industry’s most critical lifeline
📅 Published: December 11, 2025 |
📂 Category: Uncategorized
